Efficacy of intestinal microorganisms on immunotherapy of non-small cell lung cancer

Simple item page
dc.contributor.authorXu, Hua
dc.contributor.authorDeng, Yongchun
dc.contributor.authorZhu, Qing
dc.contributor.authorLi, Feng
dc.contributor.authorLiu, Na
dc.contributor.authorCheng, Jun
dc.contributor.authorQiu, Min
dc.date.accessioned2024-05-22T10:31:41Z
dc.date.available2024-05-22T10:31:41Z
dc.date.issued2024-05
dc.description.abstractWhile the 5-year survival rate of patients with advanced non-small cell lung cancer (NSCLC) has seen some improvement, the majority of NSCLC patients fail to respond to immunotherapy with immune checkpoint inhibitors (ICIs). It is critical to identify effective biomarkers that can enhance the efficacy of immunotherapy. The clinical data in the current study were collected from NSCLC patients treated with ICIs, and two groups were classified according to treatment effect: good group with consistent efficacy, poor group with only progressiveness. Differences in intestinal microbiota between the two groups were analyzed using 16s rRNA sequencing. Beta diversity analysis indicated differences between the two groups that were available for differentiation. Comparison of the number of common or unique operational taxonomic units (OTUs) among different groups suggested that there were 53 unique OTUs in the good group and 51 unique OTUs in the poor group. At the phylum level, there was a difference between the two groups for several bacterial groups with the highest abundance values, among which Firmicutes, Actinobacteria and Fusobacteria were more abundant in the good group. Members of the genera Bifidobacterium and Lactobacillus were abundant in the good group, while the abundance of Bacteroides was low. Biomarkers in the poor group included Bacteroides, Bacteroidetes, Bacteroidia, Bacteroidales, Bacteroidaceae and Veillonellaceae. The intestinal microbiota composition affected the immunotherapy process for NSCLC, which might offer more rational instructions for the clinical application of ICIs in NSCLC patients.en_US
dc.identifier.citationXu, Hua, Yongchun Deng, Qing Zhu, et al. 'Efficacy of Intestinal Microorganisms on Immunotherapy of Non-Small Cell Lung Cancer', Heliyon, vol. 10/no. 9, (2024), pp. e29899-e29899.en_US
dc.identifier.issnISSN 2405-8440
dc.identifier.issnEISSN 2405-8440
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/9527
dc.language.isoenen_US
dc.publisherElsevier Ltden_US
dc.subjectNon-small cell lung cancer Immunotherapy 16s rRNA Intestinal microorganisms Biomarkeren_US
dc.titleEfficacy of intestinal microorganisms on immunotherapy of non-small cell lung canceren_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
PIIS2405844024059309.pdf
Size:
4.78 MB
Format:
Adobe Portable Document Format
Description:
Journal Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences